- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on BRAF V600E Metastatic NSCLC in China
Total 52 results
-
Pierre Fabre MedicamentCompletedMelanoma | BRAF V600E Unresectable or Metastatic Melanoma | BRAF V600E Metastatic NSCLCChina
-
West China HospitalRecruitingBRAF V600E-mutated /MSS Metastatic Colorectal Cancer | Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal AntibodyChina
-
Sun Yat-sen UniversityNot yet recruitingNSCLC | BRAF V600 Mutation | MET Exon 14 MutationChina
-
Pierre Fabre MedicamentMerck KGaA, Darmstadt, GermanyActive, not recruitingMetastatic Colorectal Cancer | BRAF V600EChina
-
Pierre Fabre MedicamentPfizer; Merck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co. LtdCompletedBRAF V600E-mutant Metastatic Colorectal CancerFrance, Italy, United States, Spain, United Kingdom, Belgium, Austria, Japan, Netherlands
-
ABM Therapeutics Shanghai Company LimitedRecruitingAdvanced Solid Tumor | BRAF V600 MutationChina
-
PfizerMerck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co. Ltd; Pierre Fabre MedicamentCompletedBRAF V600E-mutant Metastatic Colorectal CancerUnited States, Spain, Korea, Republic of, United Kingdom, Australia, Czechia, Taiwan, Belgium, France, Hungary, Canada, Japan, Russian Federation, Netherlands, Israel, Germany, Turkey, Austria, Brazil, Poland, Italy, Argentina, Chile, Denmar... and more
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.CompletedLocally Advanced or Metastatic NSCLCChina
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.CompletedLocally Advanced or Metastatic NSCLCChina
-
AstraZenecaCompletedLocally Advanced or Metastatic EGFR(+) NSCLC PatientsChina
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.RecruitingLocally Advanced or Metastatic NSCLCChina
-
Novartis PharmaceuticalsCompleted
-
AstraZenecaCompletedLocally Advanced or Metastatic NSCLCKorea, Republic of, China, Japan
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedAdvanced or Metastatic NSCLCChina
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Not yet recruitingAdvanced or Metastatic NSCLCChina
-
The First Affiliated Hospital of Guangzhou Medical...UnknownPulmonary Metastases | NSCLCChina
-
Jiangsu Simcere Pharmaceutical Co., Ltd.UnknownAdvanced or Metastatic Gastric Cancer | Advanced or Metastatic CRC | Advanced or Metastatic Liver Cancer | Advanced or Metastatic Non Squamous NSCLCChina
-
The First Affiliated Hospital with Nanjing Medical...RecruitingMetastatic NSCLC | Recurrent NSCLC | Advanced Non-Small Cell Squamous Lung CancerChina
-
Guangdong Provincial People's HospitalShanghai Junshi Bioscience Co., Ltd.RecruitingNon-Small Cell Lung Cancer | BRAF V600 Mutation | MET Amplification | MET Exon 14 Skipping Mutation | RET Driver Mutation | Erb-B2 Receptor Tyrosine Kinase Exon 20 MutationChina
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
Sichuan UniversityRecruitingNSCLC | PD-1 Inhibitor | Leptomeningeal Metastasis | Low Dose RadiotherapyChina
-
AstraZenecaCompletedLocally Advanced or Metastatic NSCLCChina
-
MediLink Therapeutics (Suzhou) Co., Ltd.RecruitingBreast Cancer | NSCLC | HNSCC | Locally Advanced or Metastatic Solid TumorsChina
-
Second Affiliated Hospital of Nanchang UniversityJiangsu Hansoh Pharmaceutical Co., Ltd.Not yet recruitingNSCLC | EGFR Activating Mutation | Leptomeningeal MetastasisChina
-
Suzhou Junjing BioSciences Co., Ltd.Sponsor GmbHRecruitingLocally Advanced or Metastatic NSCLCChina
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.UnknownLocally Advanced or Metastatic NSCLCChina
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.RecruitingHase 1/2 Study of HS-10375 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)Advanced or Metastatic NSCLCChina
-
Shanghai JMT-Bio Inc.Active, not recruitingLocal Advanced or Metastatic NSCLC | Harboring EGFR Common MutationChina
-
Peking Union Medical CollegeRecruitingNSCLC | Brain Metastases | Furmonertinib | EGFR-mutationChina
-
Second Affiliated Hospital, School of Medicine,...Changxing People's HospitalRecruitingUnresectable Colon Cancer Peritoneal Metastases | PMMR/Ras/BRAF Wild-typeChina
-
Henan Cancer HospitalRecruitingNSCLC | Brain Metastases | Leptomeningeal MetastasisChina
-
TYK Medicines, IncActive, not recruitingNSCLC | Brain Metastases | EGFR Activating Mutation | Leptomeningeal MetastasisChina
-
Qianfoshan HospitalRecruitingMetastatic NSCLC | Locally Advanced Non-Small Cell Lung CancerChina
-
TYK Medicines, IncRecruitingNSCLC | Brain Metastases | EGFR Activating MutationChina
-
AmgenActive, not recruitingKRAS p, G12c Mutated /Advanced Metastatic NSCLCFinland, United States, Canada, Belgium, Spain, Korea, Republic of, Netherlands, United Kingdom, Australia, Denmark, Hungary, Sweden, Taiwan, Greece, Russian Federation, Switzerland, France, Italy, Japan, Poland, Brazil, Germany, Po...
-
Hubei Cancer HospitalRecruiting
-
Zhejiang Cancer HospitalRecruitingBrain Metastases | NSCLC Stage IV | ImmunotherapyChina
-
Xiaorong DongUnknownBrain Metastases | NSCLC Stage IV | Sintilimab | SRSChina
-
Sun Yat-sen UniversityCompletedBrain Metastases | NSCLC Stage IV | PD-1 AntibodyChina
-
Sichuan Provincial People's HospitalUnknownStage IV EGFR Mutated NSCL With Brain MetastasesChina
-
Fudan UniversityRecruitingBrain Metastases | SCLC,Extensive StageChina
-
Daiichi SankyoMerck Sharp & Dohme LLC; AstraZenecaActive, not recruitingAdvanced or Metastatic NSCLCUnited States, Spain, Taiwan, Japan, Italy
-
AkesoNot yet recruitingLocally Advanced or Metastatic NSCLCChina
-
Chongqing University Cancer HospitalRecruitingNon-Small Cell Lung Cancer (NSCLC)China
-
Suzhou Puhe Pharmaceutical Technology Co., LTDNot yet recruitingAdvanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)China
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
-
TakedaActive, not recruitingAdvanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)United States, Spain, France, Korea, Republic of, Hong Kong, Australia, Taiwan, United Kingdom, Canada, Turkey, Italy, China, Germany, Japan, Austria, Belgium, Greece, Israel, Netherlands, Portugal, Russian Federation, Singapore, Sw... and more
-
ArriVent BioPharma, Inc.RecruitingAdvanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768IUnited States, Australia, Spain, United Kingdom, France, Italy, China, Korea, Republic of, Canada, Japan, Netherlands
-
BeiGeneActive, not recruitingNonsmall Cell Lung Cancer, Stage IV | Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)United States, China, Korea, Republic of, France, Spain, Australia, Austria